Full Text PDF Similar Articles Mail to Author

¹Department of Pathology, Niğde Ömer Halisdemir University, Faculty of Medicine, Niğde-Turkey
²Department of Medical Biology, Niğde Ömer Halisdemir University, Faculty of Medicine, Niğde-Turkey
³Department of Program of Medical Laboratory Techniques, Eskişehir Osmangazi University, Vocational Scholl of Health Services, Eskişehir-Turkey
⁴Department of Biotechnology, Niğde Ömer Halisdemir University, Faculty of Science Literature, Niğde-Turkey DOI : 10.5505/tjo.2019.2100 Stomach cancer is the third leading cause of death among cancer-related deaths in the world. Signet-ring cell carcinoma (SRCC), a type of gastric adenocarcinoma, is frequently diagnosed in people aged fifty or older, and its incidence increases with age, but SRCC is rare in young age groups. In general, this type of cancer is thought to be more aggressive and has a worse prognosis than other types of gastric cancer. However, there are uncertainties about the characteristics and survival outcomes. Since the diagnostic tools used in patients with SRCC have low sensitivity and specificity in diagnosis and prognosis, it is important to support the diagnosis, follow-up of treatment and relapse with molecular genetic biomarkers. The aim in the current case is to see if TP53, which is the most frequently mutated gene in SRCC and NF1, that is expressed as one of the largest genes in the human genome and classified as a tumor suppressor gene, can be used as a prognostic genetic biomarker in the pathogenesis of early SRCCIt is predicted that P53 may be a determinant factor in the pathogenesis of SRCC due to the mutation burden in this case. Keywords : Gastric cancer; NF1; signet ring cell gastric cancer; TP53